Acadia Healthcare Company, Inc. (ACHC) vs Arcutis Biotherapeutics, Inc. (ARQT)

A side-by-side comparison of Acadia Healthcare Company, Inc. and Arcutis Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ACHC vs ARQT

growth of $100 · dividends reinvested · last 7y
ACHC -10.6% (-1.6%/yr)ARQT +15.4% (+2.1%/yr)ARQT compounded faster over this window
0100200Start $100202120222023202420252026$89$115
ACHC ARQT

ACHC vs ARQT: by the numbers

  • •ARQT is the larger company ($3.04B vs $2.68B market cap).
  • •ARQT is profitable (6.15% net margin) while ACHC runs a net loss (-33.44%).

Metrics side by side

Valuation

MetricACHCARQT
P/E ratioN/A116.69
Forward P/E18.8848.94
P/S ratio0.806.56
P/B ratio1.3613.80
EV / EBITDA9.4983.95
FCF yieldN/A1.29%

Profitability

MetricACHCARQT
Gross margin17.61%91.14%
Operating margin10.06%-3.25%
Net margin-33.44%6.15%
ROE-56.91%12.93%
ROIC6.69%9.95%

Growth (annualized)

MetricACHCARQT
Revenue CAGR (5Y)8.67%N/A
Total return CAGR (5Y)-13.91%-0.28%

Frequently asked

Is ACHC or ARQT more profitable?
ARQT runs the higher net margin — ACHC at -33.44% versus ARQT at 6.15%.
How have ACHC and ARQT total returns compared?
Over the past 5 years, ACHC delivered -13.91% and ARQT delivered -0.28% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.